Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis
Clearmind agrees to buy a majority stake in Charging Robotics and provide a $1.5 million loan tied to the target’s future cash flows.
Rhea-AI Summary
Clearmind Medicine (CMND) signed a definitive agreement to acquire a 51% stake in EV wireless charging company Charging Robotics for an aggregate purchase price of $2.5 million.
Charging Robotics develops proprietary intelligent wireless charging systems delivering up to 10 kW of continuous power for automated parking facilities, autonomous mobile platforms and robotaxi operations, where traditional plug-in infrastructure is not practical. Its systems integrate into robotic parking platforms and autonomous vehicle workflows, enabling fully automated charging without manual cable connection or conventional charging stations.
As a condition to closing, Clearmind will extend a $1.5 million loan to Charging Robotics bearing 4% annual interest, maturing three years after closing unless extended automatically if the borrower has not yet generated sufficient positive cash flow and available financing to repay. The acquisition closing is expected during the week of September 7, 2026, subject to customary conditions.
Positive
- 51% majority stake in Charging Robotics secured for a $2.5 million purchase price
- Additional $1.5 million loan at 4% interest supports Charging Robotics’ operations on defined terms
- Loan repayment terms allow automatic extension until sufficient cash flow, potentially reducing default risk while preserving interest income
Negative
- Total committed capital of $4.0 million (purchase price plus loan) concentrates financial exposure to Charging Robotics
- Loan principal and interest repayment may be delayed beyond three years if Charging Robotics lacks sufficient positive cash flow
Market reaction after 51% stake acquisition: CMND +27.74%
Following this news, CMND has gained 27.74%, reflecting a significant positive market reaction. Argus tracked a peak move of +10.7% during the session. Argus tracked a trough of -25.3% from its starting point during tracking. Our momentum scanner has triggered 33 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $2.17. Trading volume is exceptionally heavy at 4759.5x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
Previous Acquisition Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 03 | Acquisition LOI | Positive | -3.5% | Letter of intent announced for 51% wireless EV charging stake |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The tag-specific acquisition record showed a negative reaction to the prior letter of intent, diverging from the generally positive nature of the announcement.
Key Terms
ifrs financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Charging Robotics is one of the few worldwide developing innovative wireless charging systems designed specifically for automated parking facilities and autonomous mobile platforms- environments where conventional cables and plug-in infrastructure cannot operate.
Vancouver, Canada, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation psychedelic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that it has entered into a definitive agreement (“Agreement”) to acquire a
Charging Robotics develops dedicated intelligent wireless charging systems designed specifically for automated parking facilities, autonomous mobile platforms, and robotaxi operations, environments where conventional cables and plug-in infrastructure cannot operate. Its proprietary technology delivers continuous charging of up to 10 kW, with smart vehicle communication and dynamic energy management that allocates power in real time. The system integrates directly into robotic parking platforms and autonomous vehicle workflows, requiring no manual connection and no traditional charging stations. The technology is designed to make EV charging a background function of smart parking and autonomous mobility, improving utilization, safety, and the end-user experience in dense urban settings.
Under the terms of the Agreement, Clearmind will acquire the majority stake of Charging Robotics for an aggregate purchase price of
Unless earlier repaid, the outstanding principal amount of the Loan, together with accrued and unpaid interest, will become due and payable on the three-year anniversary of the Closing. If, as of that date, Charging Robotics has not generated positive cash flow from its operating and financing activities, together with available financing sources, sufficient to repay the outstanding loan amount, as reflected in its most recently completed financial statements prepared in accordance with IFRS, the repayment date will automatically be extended until the first date on which Charging Robotics has generated such cash flow and available financing sources. During any extension period, the outstanding principal amount will continue to accrue interest at the rate of
The Closing of the Acquisition is expected to occur during the week of September 7, 2026, subject to the satisfaction of certain closing conditions.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and completion of the acquisition and the satisfaction of closing conditions related to the acquisition. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
